Singapore Pharmaceuticals and Healthcare Report Q2 2016
BMI View: Non-communicable disease will continue to dominate Singapore’s epidemiological profile,
creating strong commercial opportunities for medicines addressing these illnesses. Companies seeking to
benefit from these revenue earning prospects will have to compete with the population’s ongoing use of
alternative treatments as a supplement to conventional medicine.
Headline Expenditure Projections
? Pharmaceuticals: SGD1.10bn (USD798mn) in 2015 to SGD1.15bn (USD790mn) by 2016; +5.1% in
local currency terms and -0.9% in USD terms.
? Healthcare: SGD19.67bn (USD14.31bn) in 2015 to SGD21.15bn (USD14.50bn) by 2016; +7.5% in
local currency terms and 1.3% in USD terms.
BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Singapore 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Singapore 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020) 22
OTC Medicine Market Forecast 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Singapore 2012-2020) 24
Pharmaceutical Trade Forecast 25
Table: Pharmaceutical Trade Data And Forecasts (Singapore 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Singapore 2014-2020) 27
Industry Risk/Reward Index 28
Asia Pacific Risk/Reward Index 28
Singapore Risk/Reward Index 34
Rewards 34
Risks 34
Regulatory Review 35
Table: Regulatory Process Time Taken Under The CECA And Under The Abridged GDA 37
Intellectual Property Issues 38
Pricing And Reimbursement Regime 39
Market Overview 44
Healthcare Sector 44
Table: Health Funding Sources In Singapore (SGDmn) 49
Table: Healthcare Resources (Singapore 2010-2015) 53
Table: Healthcare Activity (Singapore 2010-2015) 53
Table: Healthcare Personnel (Singapore 2010-2015) 53
Research & Development 54
Clinical Trials 56
Epidemiology 57
Table: Estimated Number Of New Cases Of Cancer In Singapore 58
Competitive Landscape 61
Research-Based Industry 61
Table: Multinational Pharmaceutical Firm Presence In Singapore 61
Table: Multinational Market Activity 62
Table: Leading Generic Drugmakers In Singapore 64
Pharmaceutical Distribution 65
Pharmaceutical Retail Sector 68
Company Profile 70
Baxter 70
GlaxoSmithKline 72
Haw Par 75
Merck & Co 78
MerLion 81
Novartis 84
Pfizer 87
Sanofi 90
Sci Gen 92
Demographic Forecast 95
Demographic Outlook 95
Table: Population Headline Indicators (Singapore 1990-2025) 96
Table: Key Population Ratios (Singapore 1990-2025) 96
Table: Urban/Rural Population & Life Expectancy (Singapore 1990-2025) 97
Table: Population By Age Group (Singapore 1990-2025) 97
Table: Population By Age Group % (Singapore 1990-2025) 98
Glossary 100
Methodology 102
Pharmaceutical Expenditure Forecast Model 102
Healthcare Expenditure Forecast Model 102
Notes On Methodology 103
Risk/Reward Index Methodology 104
Index Overview 105
Table: Pharmaceutical Risk/Reward Index Indicators 105
Indicator Weightings 106
List of Tables
Table: Headline Pharmaceuticals & Healthcare Forecasts (Singapore 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Singapore 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Singapore 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Singapore 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Singapore 2014-2020)
Table: Regulatory Process Time Taken Under The CECA And Under The Abridged GDA
Table: Health Funding Sources In Singapore (SGDmn)
Table: Healthcare Resources (Singapore 2010-2015)
Table: Healthcare Activity (Singapore 2010-2015)
Table: Healthcare Personnel (Singapore 2010-2015)
Table: Estimated Number Of New Cases Of Cancer In Singapore
Table: Multinational Pharmaceutical Firm Presence In Singapore
Table: Multinational Market Activity
Table: Leading Generic Drugmakers In Singapore
Table: Population Headline Indicators (Singapore 1990-2025)
Table: Key Population Ratios (Singapore 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Singapore 1990-2025)
Table: Population By Age Group (Singapore 1990-2025)
Table: Population By Age Group % (Singapore 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators